Why choose us?

Image

We build trusting relationships by delivering consistent quality

Image

We are as passionate about our people, as they are about their work

Image

We deliver high productivity through collaboration, teamwork and support

CROS NT Ltd Announces Acquisition of MDSL International Ltd.

London, United Kingdom (7 January 2014) - As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International - a specialist clinical Contract Research Organization (CRO) providing biometrics services such as Clinical Data Management and Statistical services. The financial details of the transaction remain confidential.

CROS NT Ltd, the UK branch of CROS NT, sees the acquisition as an important part of the overall group strategy. The deal adds additional resources to the existing group in the UK and will provide a new headquarters for the UK company in Maidenhead, close to London. MDSL International has built a reputation for providing strong consultancy and project work coupled with excellent customer service.

Find the full story on our news page.

Data Management

Image

For sponsors it is critical that solution providers employ effective methods and expertise in clinical data management. For us accuracy is not a static measure but an advancing and challenging standard.

Statistics

Image

For over 15 years MDSL International has led the way in innovative statistical solutions. We are the bio-statistical partner of choice for many of Europe's mid-sized pharmaceutical companies as well as the virtual development team for ambitious start-up companies.

Consultancy

Image

Our range of consultancy products has been designed to support our clients' clinical needs at various levels from program development, through protocol design to regulatory submission.

Investor Advice

Image

Our role, as an advisory service to the financial sector of the life science investment industry, is to micro analyse the trial data, to give you the detail behind the product’s performance, to ensure sophisticated investors can make the best investment choices and minimise risk.